FLT3LG and neoplasm: To test whether the specific anti-tumor immune response was maintained long-term and in the absence of adoptively transferred T cells, mice with complete remissions in Fig. 3b were re-challenged with GFP+ A20 tumors in the opposite flank 60 days after completed NDV or NDV-Flt3L treatment.